AbbVie and Johnson & Johnson are one step closer to a new use for Imbruvica. The companies went to the FDA with an app for first-line use in chronic lymphocytic leukemia (CLL), in a march toward a set of new indications the companies will need to hit their ambitious goals for the med.
Just a year after switching U.S. media buying partners, Johnson & Johnson is taking its $1 billion media account back to J3, a J&J-dedicated unit inside Interpublic Group's UM.
SGLT2 drugs recently looked as though they might get a classwide boost when partners Eli Lilly and Boehringer Ingelheim announced a cardiac benefit for their entrant, Jardiance. But just a few weeks later, the FDA has handed Johnson & Johnson a safety setback that could give its SGLT2 rivals an advantage.
Apparently you can go home again. Just a year after switching U.S. media buying partners, Johnson & Johnson is taking its $1 billion media account back to J3, a J&J-dedicated unit inside Interpublic Group's UM, reports Advertising Age.
The FDA is adding a warning about the risk for bone fractures and concerns about decreased bone density to the label for Johnson & Johnson's hot-selling SGLT2 inhibitor Invokana.
Johnson & Johnson made a big splash in November when it garnered FDA approval for the first integrated insulin pump-continuous glucose monitor device, the Animas Vibe. Now small-cap Tandem Diabetes Care has nabbed the next nod from the agency for an insulin pump with an integrated CGM, the t:slim G4 Insulin Pump.
Johnson & Johnson Innovation is setting the stage for a new biotech incubator in Toronto, fitting out 40,000 square feet of lab and office space as a new home for up to 50 fledgling startups.
Long-troubled drug developer Geron is touting what it calls "unprecedented" early results for its lead cancer drug, sending the biotech's share price up as it moves forward with partner Johnson & Johnson.
Johnson & Johnson and Bayer are leading the four-horse race among new-age anticoagulants, and they're hoping some new real-world safety data for Xarelto can help keep the med in the No. 1 spot.
The FDA recently deemed corrective actions to three devices as Class 1, reserved for situations in which "there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."